西妥昔单抗联合化疗治疗晚期结直肠癌的临床观察  

Cetuximab Combjned with Chemotherapy in the Treatment of Advance Colorectal Cancer

作　　者：胡凤[1] 王强[1] 王晓红[1] 刘永刚[1] 

机构地区：[1]包头市肿瘤医院,内蒙古包头014030

出　　处：《内蒙古医学杂志》2010年第6期658-660,共3页Inner Mongolia Medical Journal

摘　　要：目的:观察西妥昔单抗联合FOLFIR方案对比单用FOLFIRI方案治疗晚期结直肠癌的近期疗效及毒副反应。方法:28例经病理组织学确诊的晚期结直肠癌患者,随机分为两组,12例给予西妥昔单抗联合FOLFIRI方案治疗,西妥昔单抗首次给予负荷剂量400 mg/m2,每周给予维持剂量为250 mg/m2。FOLFIRI方案(CPT-11 180 mg/m2第1 d;CF200 mg/m2第1 d、第2 d;5-FU400 mg/m2静推,第1 d、第2d;5-FU600 mg/m2持续静滴22 h,第1 d、第2 d,每2周重复),16例单用FOILFIRI方案。结果:西妥昔单抗联合FOLFIRI方案全组12例患者中,完全缓解(CR)2例,部分缓解(PR)3例,稳定(SD)3例,进展(PD)4例,有效率为41.6%,疾病控制率为66.6%,中位肿瘤进展时间为(TTP)6.5个月;16例单用FOLFIRI方案,有效率为31.2%,疾病控制率为50%。西妥昔单抗联合FOLFIRI方案主要毒副反应为皮疹,腹泻和粒细胞减少。结论:西妥昔单抗联合FOLFIRI方案治疗晚期结直肠癌疗效较好,毒副反应可耐受。Objective：To determine the efficacy and tolerability of cetuximab combined with FOLFIRI regimen in the treatment of advance colorectal cancer.Methods：28 patients of advance colorectal cancer were approved by pathology in our study and divided into 2 groups,12 patients were treated with cetuximab combined with FOLFIRI,cetuximab was given by 400 mg/m^2 at feast time and subsequent weekly dose of 250 mg/m^2.FOLFIRI regimen（CPT-11 180 mg/m^2 The firth day;CF 200 mg/m^2 The firth day and the second day;5-FU 400 mg/m^2 iv,The firth day and the second day;5-FU 600 mg/m^2 civ 22 h,The firth day and the second day,every 2 weeks was a cycle.）.16 patients were treated with FOLFIRI alone.Results：CR in 2 pts,PR in 3 pts,SD in 2 pts,PD in 2 pts,the overall response rate of 41.6%,the disease control rate was 66.6%,the median time of tumor progression was 6.5 months in cetuximab combined with FOLFIRI group.overall response rate of 31.2%,the disease control rate was50% in FOLFIRI group.The common treatment related adverse event were skin rash,diarrhea and nutropenia.Conclusion：Cetuximab combined with FOLFIRI chemotherapy is an effective treatment in the advance colorectal cancer and better-tolerated alternative.

关 键 词：结直肠癌 西妥昔单抗 化学治疗 

分 类 号：R730.53[医药卫生—肿瘤] R735.3[医药卫生—临床医学]